Yahoo
NasdaqCM - Nasdaq Real Time Price USD

HeartSciences Inc. (HSCS)

3.0800 -0.0100 (-0.32%)
As of 9:39:29 AM EDT. Market Open.
Chart Range Bar
Loading chart for HSCS
  • Previous Close 3.0900
  • Open 3.1000
  • Bid 3.2800 x 200
  • Ask 5.4000 x 200
  • Day's Range 3.0800 - 3.1000
  • 52 Week Range 1.6300 - 5.2500
  • Volume 19,297
  • Avg. Volume 156,187
  • Market Cap (intraday) 14.919M
  • Beta (5Y Monthly) 1.77
  • PE Ratio (TTM) --
  • EPS (TTM) -3.2100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 12.00

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

heartsciences.com

14

Full Time Employees

April 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 10/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HSCS
0.32%
S&P 500 (^GSPC)
13.76%

1-Year Return

HSCS
12.99%
S&P 500 (^GSPC)
17.21%

3-Year Return

HSCS
91.81%
S&P 500 (^GSPC)
79.94%

5-Year Return

HSCS
99.03%
S&P 500 (^GSPC)
75.47%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 2.1k
Earnings -3.17M
Profit Margin -151,063.81%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

-3M
-2M
-1M
0
-150000.0%
-100000.0%
-50000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

12.00
12.00 Average
3.0800 Current
12.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/24/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 9.2 -> 8

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    21.94M

  • Enterprise Value

    25.91M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.25k

  • Price/Book (mrq)

    70.85

  • Enterprise Value/Revenue

    5.73k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -116.44%

  • Return on Equity (ttm)

    -1,851.90%

  • Revenue (ttm)

    4.52k

  • Net Income Avi to Common (ttm)

    -10.26M

  • Diluted EPS (ttm)

    -3.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.91k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.24M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

3.0800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: